BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32203209)

  • 41. Down-regulation of Notch-1 expression decreases PU.1-mediated myeloid differentiation signaling in acute myeloid leukemia.
    Chen PM; Yen CC; Wang WS; Lin YJ; Chu CJ; Chiou TJ; Liu JH; Yang MH
    Int J Oncol; 2008 Jun; 32(6):1335-41. PubMed ID: 18497996
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor SHB gene expression affects disease characteristics in human acute myeloid leukemia.
    Jamalpour M; Li X; Cavelier L; Gustafsson K; Mostoslavsky G; Höglund M; Welsh M
    Tumour Biol; 2017 Oct; 39(10):1010428317720643. PubMed ID: 28982308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. LncRNA HOTTIP promotes proliferation and cell cycle progression of acute myeloid leukemia cells.
    Zhuang MF; Li LJ; Ma JB
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2908-2915. PubMed ID: 31002141
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Solute Carrier Family 2 Genes Are Potential Prognostic Biomarkers in Acute Myeloid Leukemia.
    Lai B; Lai Y; Zhang Y; Zhou M; Sheng L; OuYang G
    Technol Cancer Res Treat; 2020; 19():1533033819894308. PubMed ID: 31918632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of purine-rich element binding protein B as a novel biomarker in acute myelogenous leukemia prognostication.
    Kelm RJ; Lamba GS; Levis JE; Holmes CE
    J Cell Biochem; 2018 Feb; 119(2):2073-2083. PubMed ID: 28834593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Methylation-associated DOK1 and DOK2 down-regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia.
    He PF; Xu ZJ; Zhou JD; Li XX; Zhang W; Wu DH; Zhang ZH; Lian XY; Yao XY; Deng ZQ; Lin J; Qian J
    J Cell Physiol; 2018 Sep; 233(9):6604-6614. PubMed ID: 29150948
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
    Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
    Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status.
    Shrestha R; Sakata-Yanagimoto M; Maie K; Oshima M; Ishihara M; Suehara Y; Fukumoto K; Nakajima-Takagi Y; Matsui H; Kato T; Muto H; Sakamoto T; Kusakabe M; Nannya Y; Makishima H; Ueno H; Saiki R; Ogawa S; Chiba K; Shiraishi Y; Miyano S; Mouly E; Bernard OA; Inaba T; Koseki H; Iwama A; Chiba S
    Blood Adv; 2020 Mar; 4(5):845-854. PubMed ID: 32126143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ten-Eleven Translocation-2 (Tet2) Is Involved in Myogenic Differentiation of Skeletal Myoblast Cells in Vitro.
    Zhong X; Wang QQ; Li JW; Zhang YM; An XR; Hou J
    Sci Rep; 2017 Mar; 7():43539. PubMed ID: 28272491
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TBC1D16 predicts chemosensitivity and prognosis in adult acute myeloid leukemia (AML) patients.
    Liu H; Chen P; Yang YL; Zhu KW; Wang T; Tang L; Liu YL; Cao S; Zhou G; Zeng H; Zhao XL; Zhang W; Chen XP
    Eur J Pharmacol; 2021 Mar; 895():173894. PubMed ID: 33476656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The incidence of TET2 gene mutation and its clinical significance in acute myeloid leukemia patients].
    Wei JF; Chen GH; Qiu HY; Fu CC; Ding ZX; Liu H; Feng YF; Chen SN; Chang WR; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):304-7. PubMed ID: 21729597
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High expression of lnc-CRNDE presents as a biomarker for acute myeloid leukemia and promotes the malignant progression in acute myeloid leukemia cell line U937.
    Wang Y; Zhou Q; Ma JJ
    Eur Rev Med Pharmacol Sci; 2018 Feb; 22(3):763-770. PubMed ID: 29461608
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of PIM-2 and NF-κB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival.
    Kapelko-Słowik K; Urbaniak-Kujda D; Wołowiec D; Jaźwiec B; Dybko J; Jakubaszko J; Słowik M; Kuliczkowski K
    Postepy Hig Med Dosw (Online); 2013 Jun; 67():553-9. PubMed ID: 23752607
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
    Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
    Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutation in TET2 in myeloid cancers.
    Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
    N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukaemia: relationship to somatic gene mutations affecting epigenetic pathways.
    Magotra M; Sakhdari A; Lee PJ; Tomaszewicz K; Dresser K; Hutchinson LM; Woda BA; Chen BJ
    Histopathology; 2016 Dec; 69(6):1055-1065. PubMed ID: 27458708
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Pasca S; Jurj A; Tomuleasa C; Zdrenghea M
    Medicina (Kaunas); 2020 Nov; 56(12):. PubMed ID: 33255417
    [No Abstract]   [Full Text] [Related]  

  • 59. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.
    Chou WC; Chou SC; Liu CY; Chen CY; Hou HA; Kuo YY; Lee MC; Ko BS; Tang JL; Yao M; Tsay W; Wu SJ; Huang SY; Hsu SC; Chen YC; Chang YC; Kuo YY; Kuo KT; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
    Blood; 2011 Oct; 118(14):3803-10. PubMed ID: 21828143
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CUEDC2, a novel interacting partner of the SOCS1 protein, plays important roles in the leukaemogenesis of acute myeloid leukaemia.
    Wu QY; Zhu YY; Liu Y; Wei F; Tong YX; Cao J; Zhou P; Niu MS; Li ZY; Zeng LY; Li F; Xu KL
    Cell Death Dis; 2018 Jul; 9(7):774. PubMed ID: 29991678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.